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Abstract 
While N-heterocyclic carbenes (NHC) are ubiquitous ligands in catalysts for organic or 
industrial synthesis, their potential to form transition metal complexes for medicinal 
applications has still to be exploited. Within this frame, new Au(I)-NHC compounds have been 
synthesized and structurally characterized via different methods. The solid state structure of 
one of these compounds was also established by X-ray crystallography. Of note, three of 
them bear a pentafluorophenolic ester group as a possible “activable” moiety for further 
functionalization, which allowed tethering an alkyl amine ligand or another Au(I)-phosphine 
complex featuring a pendant amine function via microwave activation. The obtained 
compounds have been tested for their antiproliferative effects in human ovarian cancer A2780 
cells, and in non-tumorigenic human embryonic kidney HEK-293T cells, showing promising 
anticancer properties and a certain selectivity towards cancerous cells. 
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1. Introduction 
Currently, metal-based drugs are used in clinic in a regular basis as anticancer 
chemotherapic agents. In fact, the platinum-based drugs cisplatin, carboplatin and oxaliplatin, 
are present in more than 75% of anticancer chemotherapic cocktails.1, 2 However, despite 
their great clinical success, these drugs present major drawbacks such as the limited 
spectrum of action, development of resistance, and severe side effects that narrowed their 
range of applicability. To overcome such drawbacks, one of the most explored strategies 
consisted in the replacement of platinum by other transition metals. This approach already 
gave promising results in the case of ruthenium, iron, gold and titanium coordination and 
organometallic compounds among others.3-8 In particular, gold(I) complexes have appeared 
in the last decades as very potent cytotoxic agents;9-12 the most famous example being 
((2,3,4,6-tetra-O-acetyl-1-(thio-kS)--D-glucopyranosato)(triethylphosphine)gold(I)) 
(auranofin) already in the clinic as anti-arthritis agent (Figure 1).13 As a matter of fact, gold is 
the most noble of the elements and it certainly holds a central place in the world of finance, 
art and jewelry. Nowadays, the medicinal uses of gold compounds are the subject of intense 
studies. Conspicuous experimental evidence has been gathered so far to suggest that the 
pronounced antiproliferative effects caused by gold compounds most likely arise from 
innovative mechanisms of action in comparison to established anticancer drugs. 
Following the successful application of gold phosphine complexes as antitumor agents, 
Berners-Price and coworkers have pioneered the application of a variety of cationic 
mononuclear gold(I) N-heterocyclic (NHC) biscarbene complexes as potential 
chemotherapeutic agents (an example is reported in Fig. 1).14 Since then a number of 
Au(I)-NHC carbene compounds have been synthesized and characterized for their biological 
properties, and the studies on this family of organometallic compounds have been reviewed 
on a regular basis in the past few years.15-18 Indeed, Au(I)-NHC compounds present a variety 
of different derivatization possibilities associated to the possible presence of an ancillary 
ligand coordinated to gold, in addition to the Au-NHC bond (e.g. phosphines, thiols, as well as 
a second NHC ligand, as depicted in Figure 1).19, 20 Contrary to platinum derivatives, it has 
been shown that several Au(I)-NHC complexes induce apoptosis via targeting mitochondria, 
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but also through the interaction with different proteins/enzymes (e.g. thioredoxin reductase).21, 
22
  
Of note, physicochemical and biological properties of metal complexes have been improved 
through various strategies, among which the concept of multinuclearity. Indeed, a number of 
platinum,23 ruthenium and gold-based homo- or heteropolynuclear complexes, either bi- or 
polymetallic, have been developed by us and others and biologically tested.24-29 
In this context, we describe here the synthesis and characterization of new Au(I)-NHC  
compounds among which three of them bear a pentafluorophenolic ester group as a possible 
“activable” moiety for further functionalization. In order to prove this concept, one of the 
Au(I)-NHC complexes was tethered a posteriori to an amine ligand or to another 
Au(I)-phosphine complex bearing a pendant amine function using microwave activation. In 
the latter case, a dinuclear Au(I) complex was obtained. The success of this strategy opens 
towards a quick route to a great diversity of structures allowing further exploration of 
synergies. Assessment of the antiproliferative properties of the new compounds in human 
ovarian cancer cells (A2780) and in a model of healthy cell (human embryonic kidney 
HEK-293T) is also reported demonstrating the suitability of these scaffolds for biological 
applications. 
 
 
 
 
Figure 1: Examples of currently studied Au(I) compounds with cytotoxic properties. 
 
 
2. Results and discussion 
2.1 Synthesis and structural characterization 
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In order to easily derivatize a NHC-ligand allowing further efficient coupling with an amine 
moiety, we selected the procedure previously described by Metzler-Nolte et al. in the case of 
ruthenium and rhodium functionalized complexes.30 Thus, the “pro-ligand” 1-methyl-3-(4-
(perfluorophenoxycarbonyl)benzyl)imidazolium bromide (L.HBr, Scheme 1) was obtained in 
two steps starting from commercial 4-bromomethylbenzoic acid and pentafluorophenol, the 
corresponding ester being then reacted with one equivalent of 1-methylimidazole. The Au(I) 
complex 1 was obtained in 75% yield by a transmetallation reaction from the in situ formed 
Ag(I) complex according to the general method described by Lin et al., and subsequent 
transfer of the NHC ligand to the gold(I) precursor [AuCl(tht)].31 The formation of 1 was 
assessed by 1H NMR spectroscopy where the disappearance of the singlet of the imidazolium 
proton at 9.37 ppm was noticed. The shift of the signal of the corresponding carbon in 
13C{1H} NMR from 139.0 ppm in the imidazolium salt to 172.4 ppm confirmed the formation of 
the carbene complex.19 An unsymmetrical cationic NHC/phosphine complex (2) was also 
synthesized in 90 % yield by reacting 1 with triphenylphosphine in the presence of silver 
tertrafluoroborate as a chloride abstractor (Scheme 1). The coordination of the 
triphenylphosphine ligand was assessed by 31P{1H} NMR, the phosphorus atom giving a 
broad singlet at 40.7 ppm characteristic of cationic Au(I)-phosphine complexes.32 Additionally, 
in 13C{1H} NMR the signal corresponding to the carbene was shifted from 172.4 ppm to 
186.4 ppm, as expected for coordination to a cationic Au(I) center. Moreover, crystals of 2 
suitable for X-Ray diffraction have been obtained by slow evaporation of a 
dichloromethane/pentane (1/4) solution. The crystal structure of this complex was solved and 
shows the typical linear two-coordinated geometry of Au(I) cation (Figure 2).  
In order to obtain a cationic bis-NHC metal derivative, we used a classical method33 starting 
from salts containing a non-halide anion, which is then reacted with silver oxide yielding the 
silver bis-NHC complex, acting as an halide abstractor and ligand transfer agent. L.HBr was 
thus reacted quantitatively with an excess of sodium tetrafluoroborate to lead to the 
tetrafluoroborate analogue L.HBF4. The latter was reacted with silver(I) oxide and half an 
equivalent of [AuCl(tht)] to afford the cationic bis-NHC complex 3 in 60% yield (Scheme 1), 
whose formation was confirmed by 13C{1H} NMR spectroscopy, where the carbene gave a 
signal at 184.4 ppm characteristic of this type of cationic Au(I) complexes.34  
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Scheme 1: Synthesis of the different Au(I)-NHC complexes bearing the pentafluophenol ester 
moiety. 
 
 
 
Figure 2: Ortep view of compound 2. Selected bond distances (Å) and angle (°): Au-P 
2.2788(13); Au-C(1) 2.034(5); P-Au-C1 177.70(16). 
 
  
Afterwards, with the aim of obtaining a bimetallic complex, we imagined the grafting of a 
Au(I)-phosphine complex, bearing a pendant amine function, directly to the Au(I)-NHC 
complex through the activated pentafluorophenol ester. However, in order to setup the 
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reacted with one equivalent of the amine in acetonitrile under microwave irradiation and the 
best reaction conditions were found to be heating at 80°C for 30 minutes (Scheme 2); higher 
temperatures lead to partial decomposition of the gold complex even when using a shorter 
reaction time. It is also worth noting that no additional base was used to prevent any 
degradation of the carbene. The coupling product (4) was simply purified by precipitation and 
obtained in very good yield (87 %).  
Applying these optimized reaction conditions, we then reacted complex 1 with the 
2-aminoethyldiphenylphophine gold(I) chloride complex and obtained the desired bimetallic 
complex (5) in very good yield (86 %) (Scheme 2).  
 
Scheme 2: Synthesis of the different Au(I)-NHC complexes through reaction of the activated 
ester moiety. 
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high-resolution mass spectrometry and elemental analysis, all these data being in agreement 
with the formation of the amide linkage.  
In an attempt to enlarge the scope of polymetallic complexes, both cationic complexes 2 and 
3 were reacted with one or two equivalents of 2-aminoethyldiphenylphosphine gold(I) chloride 
respectively. However, even though the coupling through the activated ester occurred, a 
redistribution of the ligands was observed, yielding to a mixture of products in both cases. 
 
2.2 Antiproliferative activities 
The new compounds were screened for their antiproliferative properties in human ovarian 
cancer cell lines sensitive (A2780) using the classical MTT assay (see Experimental for 
details). In addition, in order to evaluate the compounds’ selectivity for cancerous compared 
to healthy cells, the complexes were also tested in human embryonic kidney HEK-293T cells. 
A dose-dependent inhibition of cell growth was observed in all cell lines with IC50 values 
ranging from ca. 2 to 122 μM after 72 h incubation as depicted in Table 1, the most effective 
compound being the dinuclear Au(I) derivative 5. Differently from the reference gold(I) 
complex auranofin, which is very cytotoxic in all the tested cell lines, the new compounds 
display certain selective antiproliferative activities, being at least 2-fold less cytotoxic in the 
non-tumorgenic HEK-293T cells.  
 
Table 1. Cell Viability IC50 Values of compounds 1-5 in human ovarian carcinoma cell line 
A2780 or in human embryonic kidney cells (HEK-293T) after 72 h incubation. 
 IC50 
Compound A2780 HEK-293T 
1 53.0 ± 2.4 122.0 ± 6.2 
2 5.2 ± 0.7 11.2 ± 0.5 
3 19.7 ± 2.0 41.5 ± 1.4 
4 - - 
5 2.2 ± 0.4 6.2 ± 0.7 
auranofin 1.2 ± 0.5 1.7 ± 0.3 
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4. Conclusion 
We have reported here the synthesis of five neutral or cationic Au(I)-NHC complexes in good 
yields. Among them, three present the pentafluorophenolic ester functionality as a useful 
“activable” ester for further functionalization, and chlorido, NHC or triphenylphosphine as a 
second ligand. A stoichiometric base-free method for grafting an alkyl amine on gold(I) 
carbenes in high yields using microwave irradiation is also reported, which allowed the 
synthesis of two new NHC complexes: a monometallic Au(I)-NHC complex and a 
homobimetallic Au(I) complex with a NHC-phosphine bridging ligand. Each derivative has 
been fully characterized by classical methods (1H, 13C{1H}, 19F{1H} and 31P{1H} NMR 
spectroscopy, IR spectroscopy, high resolution mass spectrometry and elemental analysis). 
The structure of compound 2 has also been solved by X-Ray diffraction. 
Although more biological studies should be undertaken to further investigate the mechanisms 
of action of this new series of compounds, preliminary in vitro antiproliferative assays have 
revealed the promising cytotoxic properties of the compounds in cancer cells with respect to 
non-tumorigenic ones. Overall, we are confident that these results will allow new possibilities 
of fine-tuning of the chemico-physical properties of organometallic Au(I)-NHC scaffolds for 
biological applications. 
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5. Experimental section 
5.1 General Remarks. All reactions were carried out under an atmosphere of purified argon 
using Schlenk techniques. Solvents were dried and distilled under argon before use. The 
precursors [AuCl(tht)]35 and [AuCl(PPh2(CH2)2NH2)] have been synthesized according to 
literature procedures.29, 31 All other reagents were commercially available and used as 
received. All the analyses were performed at the “Plateforme d’Analyses Chimiques et de 
Synthèse Moléculaire de l’Université de Bourgogne”. The identity and purity (≥ 95%) of the 
complexes were unambiguously established using high-resolution mass spectrometry and 
NMR. Exact mass of the synthesized complexes were obtained on a Thermo LTQ Orbitrap 
XL. 1H- (300.13, 500.13 or 600.23 MHz), 13C- (125.77 or 150.90 MHz) and 19F-(282.38 MHz) 
NMR spectra were recorded on Bruker 300 Avance III, 500 Avance III or 600 Avance II 
spectrometers. Chemical shifts are quoted in ppm (δ) relative to TMS (1H and 13C) and CFCl3 
(19F), using the residual protonated solvent (1H) or the deuterated solvent (13C) as internal 
standards. Alternatively, 85% H3PO4 (31P) and CFCl3 as an external standard (19F). Infrared 
spectra were recorded on a Bruker Vector 22 FT-IR spectrophotometer (Golden Gate ATR). 
X-ray diffraction data for 3
 
were collected on a Nonius Kappa CCD at 115 K. Microwave 
reactions were carried on in an Anton Paar Monowave 300 apparatus. 
 
5.2 Synthesis 
1-methyl-3-{4-[(perfluorophenoxy)carbonyl]benzyl}imidazolium tetrafluoroborate 
(L.HBF4) 
A round-bottom flask was filled with 279 mg of 2 (0.60 mmol) and 200 mg of NaBF4 
(1.81 mmol) in 20 mL of acetone. The reaction was maintained at room temperature 
overnight.  After removing of acetone under vacuum, the obtained white solid was partially 
dissolved in 30 mL of dichloromethane, and filtrated through paper to give a colorless 
solution. Dichloromethane was then evaporated under vacuum to lead to the pure product (98 
% yield). RMN 1H (CDCl3, 300 MHz): 3.95 (s, 3 H, Me) 5.70 (s, 2 H, CH2), 7.74 (d, 2H, 3JH-H = 
8.5 Hz, 2 CHPh), 7.84 (d, 1 H, 3JH-H = 1.8 Hz, CHim.), 7.90 (d, 1 H, 3JH-H = 1.8 Hz, CHim.), 8.28 
(d, 2H, 3JH-H = 8.5 Hz, 2 CHPh), 9.37 (s, 1H, NCHN+). RMN 19F{1H} (CDCl3, 282.38 MHz):-
150.4 (m, BF4),  -153.6 (dt, 2 F, 3JF-F = 25.4 Hz, 4JF-F = 2.8 Hz, Fortho), -157.5 (t, 1 F, 3JF-F = 
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22.6 Hz, Fpara), -162.4 (m, 2 F, Fmeta). FT-IR (ATR, cm-1): 3166, 1759, 1613, 1574, 1518, 
1473, 1451, 1422, 1248, 1170, 1049.  Anal. Calc. for C18H11F9N2O2B: C, 45.99, H, 2.57, N, 
5.96 %. Found: C, 45.51, H, 2.39, N, 6.19. 
 
chlorido(1-methyl-3-{4-[(perfluorophenoxy)carbonyl]benzyl}imidazol-2-ylidene)gold(I) 
(1) 
A round-bottom flask was filled with 146 mg of L.HBr (0.31 mmol), 60 mg of Ag2O (0.26 
mmol), molecular sieves 4Å (MS 4Å)  (200 mg) in 16 mL of dichloromethane. The mixture was 
reacted for 4 h at room temperature in the dark. Afterwards, 101 mg of [AuCl(tht)] (0.31 mmol) 
dissolved into 5 mL of dichloromethane was added dropwise to the previous mixture and 
reacted overnight at room temperature in the dark. After a filtration over celite, the volatiles 
were removed under vacuum to give the product as a white solid. (75 % yield). RMN 1H 
(CDCl3, 300 MHz): 3.88 (s, 3 H, Me), 5.49 (s, 2 H, CH2), 6.93 (d, 1 H, 3JH-H = 1.8 Hz, CHim.), 
7.00 (d, 1 H, 3JH-H = 1.8 Hz, CHim.), 7.47 (d, 2H, 3JH-H = 8.5 Hz, 2 CHPh), 8.18 (d, 2H, 3JH-H = 8.5 
Hz, 2 CHPh). RMN 13C{1H} (CDCl3, 75.48 MHz): 38.4 (Me), 54.5 (CH2), 120.5 (CHim.), 122.7 
(CHim.), 127.4 (C1), 128.3 (CHPh), 131.5 (CHPh), 136.3 (Cperfluoro), 139.7 (Cperfluoro), 141.4 
(Cperfluoro), 141.9 (C4), 143.0 (Cperfluoro), 161,9 (C=O), 172.4 (Ccarbene). RMN 19F{1H} (DMSO-6d, 
282.38 MHz): -152.5 (dt, 2 F, 3JF-F = 25.4 Hz, 4JF-F = 2.8 Hz, Fortho), -157.7 (t, 1 F, 3JF-F = 22.6 
Hz, Fpara), -162.2 (m, 2 F, Fmeta). FT-IR (ATR, cm-1): 3094.3, 1753.4, 1610.7, 1516.4, 1466.9, 
1414.0. ESI-MS (DMSO/MeOH), positive mode exact mass for C18H11AuClF5N2O2+Na 
(636.99869): measured m/z 636.99561 [M+Na]+. Anal. Calc. for C18H11AuClF5N2O2: C, 35.17, 
H, 1.80, N, 4.56 %. Found: C, 34.58, H, 1.73, N, 4.47 %.   
   
(1-methyl-3-{4-[(perfluorophenoxy)carbonyl]benzyl}imidazole-2-ylidene)(triphenylphos
phine)gold(I) tetrafluoroborate (2) 
A Schlenk tube was filled with 40 mg of 1 (0.065 mmol) and 18.7 mg of PPh3 (0.072 mmol) 
which were dissolved into 4 mL of distilled dichloromethane. AgBF4 in solution in methanol 
was added dropwise at room temperature. The reaction was maintained for one hour during 
which a white precipitate appeared and became grey after some minutes. After a filtration 
over fritte with celite, the volatiles were removed under vacuum to afford a colorless oil which 
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gave rise to a white precipitate after being washed with Et2O. The white precipitate was 
washed with Et2O to give the pure product. (90 % yield). Crystals suitable for X-Ray diffraction 
have been obtained by slow evaporation of a solution in dichloromethane/pentane (1/4). RMN 
1H (CDCl3, 500 MHz): 3.99 (s, 3 H, Me), 5.54 (s, 2 H, CH2), 7.31 (d, 1 H, 3JH-H = 1.8 Hz, 
CHim.), 7.37 (m, 8 H, 6 Hortho/P + 2 CHPh), 7.48 (d, 1 H, 3JH-H = 1.8 Hz, CHim.), 7.50 (pseudo-t, 6 
H, 3JH-H = 7.3 Hz, 6 Hmeta/P), 7.57 (t, 3 H, 3JH-H = 7.5 Hz, 3 Hpara/P), 7.98 (d, 2H, 3JH-H = 8.5 Hz, 2 
CHPh). RMN 13C{1H} (CDCl3, 125.76 MHz): 38.7 (Me), 54.3 (CH2), 123.6 (CHim.), 123.8 
(CHim.), 126.7 (C1), 128.0 (CipsoPPh3, 1JP-C = 56.6 Hz), 128.2 (CHparaPPh3), 129.7 (CmétaPPh3, 3JP-C 
= 11.3 Hz), 131.3 (CHPh), 132.4 (CHPh), 133.9 (CorthoPPh3, 2JP-C = 13.8 Hz),  ), 137.1 (Cperfluo), 
139.1 (Cperfluo), 140.5 (Cperfluo), 142.5 (Cperfluo), 143.8 (C4), 162,2 (C=O), 186.4 (Ccarbene). RMN 
19F{1H} (CDCl3, 470.59 MHz): -152.6 (dt, 2 F, 3JF-F = 25.4 Hz, 4JF-F = 2.8 Hz, Fortho), -152.9 (m, 
BF4), -157.6 (t, 1 F, 3JF-F = 22.6 Hz, Fpara), -162.0 (m, 2 F, Fmeta). RMN 31P{1H} (CDCl3, 202.46 
MHz): 40.7 (s). FT-IR (ATR, cm-1): 1758.2, 1612.8, 1520.0, 1475.3, 1437.5. ESI-MS 
(DMSO/MeOH), positive mode exact mass for [C36H26AuF5N2O2P]+ (841.13121): mesured 
m/z 841.12857 [M-BF4]+. Anal. Calc. for C36H26AuF5N2O2PBF4: C, 46.58, H, 2.82, N, 3.02 %. 
Found: C, 46.57, H, 2.92, N, 3.04 %.   
 
bis(1-methyl-3-{4-[(perfluorophenoxy)carbonyl]benzyl}imidazole-2-ylidene)gold(I) 
tetrafluoroborate (3) 
A round-bottom flask was filled with 84.4 mg of L.HBF4 (0.18 mmol), 33 mg of Ag2O (0.14 
mmol), and molecular sieves 4Å (MS 4Å) (100 mg) in 10 mL of dichloromethane. The mixture 
was reacted for 4 h at room temperature in the dark. Then 31 mg of [AuCl(tht)] (0.09 mmol) 
dissolved into 3 mL of dichloromethane were added dropwise to the previous mixture and 
reacted overnight at room temperature in the dark. After a filtration over fritte with celite, the 
volatiles were removed under vacuum to give the product as a white solid. (60 % yield). RMN 
1H (DMSO-6d, 300 MHz): 3.83 (s, 3 H, Me), 5.53 (s, 2 H, CH2), 7.44 (d, 2H, 3JH-H = 8.5 Hz, 2 
CHPh), 7.57 (d, 1 H, 3JH-H = 1.8 Hz, CHim.), 7.65 (d, 1 H, 3JH-H = 1.8 Hz, CHim.), 8.06 (d, 2H, 3JH-
H = 8.5 Hz, 2 CHPh). RMN 13C{1H} (DMSO-6d, 125.77 MHz): 38.6 (Me), 53.9 (CH2),  123.7 
(CHim.), 124.9 (CHim.), 126.4 (C1), 129.1 (CHPh), 131.8 (CHPh), 145.6 (C4), 162.6 (C=O), 184.4 
(Ccarbene). RMN 19F{1H} (DMSO-6d, 282.38 MHz): -148.34 (d, BF4), -153.6 (d, 4 F, 3JF-F = 25.4 
 12 
Hz, Fortho), -157.7 (t, 1 F, 3JF-F = 22.6 Hz, Fpara), -162.6 (m, 2 F, Fmeta). FT-IR (ATR, cm-1): 
1759.7, 1615.9, 1521.4, 1476.1, 1439.5. ESI-MS (DMSO/MeOH), positive mode exact mass 
for [C36H22AuF10N4O4]+ (961.11414): measured m/z 961.11676 [M-BF4]+. Anal. Calc. for 
C36H22AuF14N4O0B: C, 41.24, H, 2.12, N, 5.34 %. Found: C, 41.12, H, 2.11, N, 5.45 %. 
 
General procedure for the microwave-based coupling reactions: 
A microwave 10 mL-tube was charged with 1 and H2N-CH2-R (1 eq.) dissolved in distillated 
acetonitrile. The mixture was reacted in microwave oven (quick heating from r. t. to 80°C, 850 
W, stirring at 600 rpm) at 80°C (temperature checked by IR probe) for 30 min (50 W, stirring 
at 600 rpm). After evaporation of the acetonitrile, the product was redissolved in 
dichloromethane and filtrated through celite. After partial removal of dichloromethane and 
addition of a large amount of pentane, the obtained precipitate was filtrated and dry under 
vacuum to give the pure product. 
 
chlorido{1-methyl-3-[4-(2-phenylethylcarbamoyl)benzyl]imidazol-2-ylidene}gold(I) (4) 
1 (50 mg, 0.081 mmol) was dissolved in the tube into acetonitrile (4 mL) and 2-
phenylethylamine (0.081 mmol, 10 µL) was added dropwise.  
Product as a light yellow powder (38.9 mg, 87 % yield). 1H NMR (CDCl3, 298 K, 300.13 MHz): 
2.93 (t, 2 H, 3JH-H = 6.9 Hz, CH2-Ph), 3.71 (pseudo-q, 2 H, 3JH-H = 6.9 Hz, CH2-NH), 3.86 (s, 3 
H, N-Me), 5.37 (s, 2 H, N-CH2), 6.19 (broad s, 1 H, NH), 6.88 (d, 1 H, 3JH-H = 1.8 Hz, CHIm), 
6.94 (d, 1 H, 3JH-H = 1.8 Hz, CHIm), 7.23 (m, 3 H, 3 CHPh), 7.32 (m, 4 H, 2 CHp-C6H4 + 2 CHPh), 
7.66 (d, 2 H, 3JH-H = 8.1 Hz, 2 CHp-C6H4). {1H}13C NMR (CDCl3, 300 K, 125.77 MHz): 35.6 (s, 
CH2-Ph), 38.4 (s, N-CH3), 41.2 (s, CH2-NH), 54.6 (s, CH2-N), 120.5 (s, CHIm), 122.5 (s, CHIm), 
126.7 (s, CHarom), 127.7 (s, CHarom), 128.1 (s, CHarom), 128.8 (s, CHarom), 135.2 (s, Cquat-C(O)), 
138.3 (s, , Cquat-CH2), 138.8 (s, Cquat-Ph), 166.8 (s, C=O), 172.0 (s, Ccarbene). FT-IR (ATR, cm-1): 
3349, 3109, 2934, 1640, 1535, 1500, 1464, 1408, 1307, 1236, 1191. ESI-MS (CDCl3/MeOH), 
positive mode exact mass for [C20H22AuClN3O]+ (552.11114): measured m/z 552.10972 
[M+H]+, positive mode exact mass for [C20H21AuClN3ONa]+ (574.09309): measured m/z 
574.09147 [M+Na]+. Anal. Calc. for C20H22AuN3O: C, 43.45, H, 3.84, N, 7.60 %. Found: C, 
43.58, H, 2.72, N, 7.71 %.   
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µ-(1-methyl-3-{4-[(2-diphenylphosphinoethyl)-κP-carbamoyl]benzyl}imidazol-2-ylidene)- 
κC-bis(chlorido)gold(I) (5) 
1 (67 mg, 0.11 mmol) and (2-aminoethyldiphenylphosphine-κP)chloridogold(I) (0.11 mmol, 50 
mg) were dissolved in the tube into acetonitrile (5 mL). The product was recovered as a pale 
yellow powder (85 mg, 86 % yield). 1H NMR (CDCl3, 298 K, 300.13 MHz): 2.90 (m, 2 H, CH2-
P), 3.74 (m, 2 H, CH2-NH), 3.85 (s, 3 H, N-Me), 5.36 (s, 2 H, CH2-N), 6.90 (broad s, 2 H, NH + 
CHIm), 6.96 (s, 1 H, CHIm), 7.28 (d, 2 H, 3JH-H = 8.1 Hz, 2 CHp-C6H4), 7.42-7.52 (m, 6 H, 6 
CHPh), 7.66-7.69 (m, 6H, 2 CHp-C6H4 + 4 CHPh). {1H}13C NMR (CDCl3, 300 K, 125.77 MHz): 
28.2 (d, 1JP-C = 37.7 Hz, CH2-P), 36.6 (d, 2JP-C = 5.0 Hz, CH2-NH), 38.4 (s, N-CH3), 54.5 (s, N-
CH2), 120.7 (s, CHIm), 122.5 (s, CHIm), 127.8 (s, CHp-C6H4), 127.9 (s, CHp-C6H4), 128.7 (d, 1JP-C 
= 61.6 Hz, Cquat-P), 129.4 (d, 2JP-C = 11.3 Hz, CHortho-Ph), 132.3 (d, 4JP-C = 1.3 Hz, CHpara-Ph), 
133.2 (d, 3JP-C = 13.8 Hz, CHortho-Ph), 133.9 (s, Cquat-CH2-N), 138.7 (s, Cquat-C(O)), 167.0 (s, 
C(O)), 171.8 (s, Ccarbene). {1H}31P NMR (CDCl3, 300 K, 202.45 MHz): 24.2 (broad s, -CH2-
PPh2-AuCl). FT-IR (ATR, cm-1): 3345, 3127, 3054, 2992, 2925, 1648, 1532, 1500, 1466, 
1435, 1406, 1308, 1283, 1233, 1187, 1104. ESI-MS (H2O/MeOH), positive mode exact mass 
for [C26H26Au2Cl2N3OPNa]+ (914.04138): measured m/z 914.03946 [M+Na]+. Anal. Calc. for 
C26H26Au2Cl2N3OP: C, 35.00, H, 2.94, N, 4.71 %. Found: C, 34.90, H, 2.42, N, 4.93 %.   
 
5.3 X-ray crystallography 
Crystals of 2 were obtained by slow evaporation of a dichloromethane/pentane (1/4) solution. 
Intensity data were collected on a Bruker APEX II at 115 K. The structure was solved by 
direct methods (SIR92)36 and refined with full-matrix least-squares methods based on F2 
(SHELXL-97)37 with the aid of the WINGX program.38 All non-hydrogen atoms were refined 
with anisotropic thermal parameters. Hydrogen atoms were included in their calculated 
positions and refined with a riding model. Crystallographic data are reported in Table 2. 
CCDC reference is 981279. 
 
Table 2.  Crystal data and structure refinement for 2. 
Empirical formula C36 H26 Au B F9 N2 O2 P 
Formula weight 928.33 
Temperature 115(2) K 
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Wavelength 0.71073 Å  
Crystal system, space group Triclinic,  P -1 
Unit cell dimensions a = 9.9996(5) Å    = 102.500(3)° 
 b = 11.5364(6) Å   = 95.586(2)° 
 c = 17.5029(10) Å  = 100.972(2)° 
Volume 1914.91(18) Å3 
Z, Calculated density 2,  1.610 Mg/m3 
Absorption coefficient 3.960 mm-1 
F(000) 904 
Crystal size 0.2 x 0.2 x 0.2 mm  range for data collection 1.952 to 27.461 deg. 
Limiting indices -11<=h<=11, -14<=k<=14, -20<=l<=22 
Reflections collected / unique 11851 / 7768 [R(int) = 0.0297] 
Completeness to theta = 25.242 98.1 % 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 7768 / 0 / 470 
Goodness-of-fit on F^2 1.139 
Final R indices [I>2(I)] R1 = 0.0399, wR2 = 0.0826 
R indices (all data) R1 = 0.0486, wR2 = 0.0882 
Largest diff. peak and hole 1.082 and -0.739 e.Å-3 
  
 
5.4 Antiproliferative assay 
The human ovarian cancer cell line A2780 was obtained from the European Centre of Cell 
Cultures ECACC (Salisbury, UK) and were cultured respectively in RPMI medium containing 
GlutaMaxI supplemented with 10% FBS and 1% penicillin/streptomycin (all from Invitrogen), 
at 37°C in a humidified atmosphere of 95% of air and 5% CO2 (Heraeus, Germany). Non-
tumoral human embryonic kidney cells HEK-293T were kindly provided by Dr. Maria Pia 
Rigobello (CNRS, Padova, Italy) and were cultivated in DMEM medium, added with 
GlutaMaxI (containing 10% FBS and 1% penicillin/streptomycin (all from Invitrogen) and 
incubated at 37°C and 5% CO2. For evaluation of growth inhibition, cells were seeded in 96-
well plates (Costar, Integra Biosciences, Cambridge, MA) at a concentration of 15000 
cells/well and grown for 24 h in complete medium. Solutions of the compounds were prepared 
by diluting a freshly prepared stock solution (10-2 M in DMSO) of the corresponding 
compound in aqueous media (RPMI or DMEM for the A2780 and HEK-293T, respectively). 
Afterwards, the intermediate dilutions of the compounds were added to the wells (100 μL) to 
obtain a final concentration ranging from 0 to 200 μM, and the cells were incubated for 72 h. 
Following 72 h drug exposure, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) was added to the cells at a final concentration of 0.25 mg ml-1 incubated for 2 h, then 
the culture medium was removed and the violet formazan dissolved in DMSO. The optical 
density of each well (96-well plates) was quantified three times in tetraplicates at 540 nm 
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using a multi-well plate reader, and the percentage of surviving cells was calculated from the 
ratio of absorbance of treated to untreated cells. The IC50 value was calculated as the 
concentration reducing the proliferation of the cells by 50% and it is presented as a mean (± 
SE) of at least three independent experiments. 
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